Are k13 and plasmepsin II genes, involved in Plasmodium falciparum resistance to artemisinin derivatives and piperaquine in Southeast Asia, reliable to monitor resistance surveillance in Africa?
Anti-malarial drug
Dihydroartemisinin
In vitro
K13
Malaria
Piperaquine
Plasmepsin II
Plasmodium falciparum
Resistance
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
23 Aug 2019
23 Aug 2019
Historique:
received:
04
03
2019
accepted:
17
08
2019
entrez:
25
8
2019
pubmed:
25
8
2019
medline:
18
12
2019
Statut:
epublish
Résumé
Mutations in the propeller domain of Plasmodium falciparum kelch 13 (Pfk13) gene are associated with artemisinin resistance in Southeast Asia. Artemisinin resistance is defined by increased ring survival rate and delayed parasite clearance half-life in patients. Additionally, an amplification of the Plasmodium falciparum plasmepsin II gene (pfpm2), encoding a protease involved in hemoglobin degradation, has been found to be associated with reduced in vitro susceptibility to piperaquine in Cambodian P. falciparum parasites and with dihydroartemisinin-piperaquine failures in Cambodia. The World Health Organization (WHO) has recommended the use of these two genes to track the emergence and the spread of the resistance to dihydroartemisinin-piperaquine in malaria endemic areas. Although the resistance to dihydroartemisinin-piperaquine has not yet emerged in Africa, few reports on clinical failures suggest that k13 and pfpm2 would not be the only genes involved in artemisinin and piperaquine resistance. It is imperative to identify molecular markers or drug resistance genes that associate with artemisinin and piperaquine in Africa. K13 polymorphisms and Pfpm2 copy number variation analysis may not be sufficient for monitoring the emergence of dihydroartemisinin-piperaquine resistance in Africa. But, these markers should not be ruled out for tracking the emergence of resistance.
Identifiants
pubmed: 31443646
doi: 10.1186/s12936-019-2916-6
pii: 10.1186/s12936-019-2916-6
pmc: PMC6708145
doi:
Substances chimiques
Antimalarials
0
Artemisinins
0
Protozoan Proteins
0
Quinolines
0
artenimol
6A9O50735X
piperaquine
A0HV2Q956Y
Aspartic Acid Endopeptidases
EC 3.4.23.-
plasmepsin II
EC 3.4.23.39
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
285Références
Mol Microbiol. 2000 May;36(4):955-61
pubmed: 10844681
Lancet. 2005 Dec 3;366(9501):1960-3
pubmed: 16325698
J Infect Dis. 2006 Aug 15;194(4):528-35
pubmed: 16845638
N Engl J Med. 2008 Dec 11;359(24):2619-20
pubmed: 19064625
N Engl J Med. 2009 Jul 30;361(5):455-67
pubmed: 19641202
Antimicrob Agents Chemother. 2010 May;54(5):1872-7
pubmed: 20160056
Antimicrob Agents Chemother. 2010 Jun;54(6):2455-64
pubmed: 20350946
Antimicrob Agents Chemother. 2010 Jul;54(7):2886-92
pubmed: 20421395
Antimicrob Agents Chemother. 2010 Sep;54(9):3537-44
pubmed: 20547801
Clin Infect Dis. 2010 Dec 1;51(11):e82-9
pubmed: 21028985
Malar J. 2011 Nov 10;10:339
pubmed: 22074219
Lancet. 2012 May 26;379(9830):1960-6
pubmed: 22484134
PLoS One. 2012;7(5):e30927
pubmed: 22701513
Emerg Infect Dis. 2013 May;19(5):814-5
pubmed: 23697703
Lancet Infect Dis. 2013 Dec;13(12):1043-9
pubmed: 24035558
Antimicrob Agents Chemother. 2013 Dec;57(12):6196-204
pubmed: 24080667
Sci Rep. 2013 Nov 25;3:3318
pubmed: 24270944
Malar J. 2013 Nov 25;12:431
pubmed: 24274185
Nature. 2014 Jan 2;505(7481):50-5
pubmed: 24352242
Lancet Infect Dis. 2014 Jun;14(6):449-50
pubmed: 24849722
Antimicrob Agents Chemother. 2014 Aug;58(8):4935-7
pubmed: 24867977
J Infect Dis. 2014 Dec 15;210(12):2001-8
pubmed: 24994911
N Engl J Med. 2014 Jul 31;371(5):411-23
pubmed: 25075834
J Infect Dis. 2015 Mar 1;211(5):680-8
pubmed: 25180240
J Infect Dis. 2015 Mar 1;211(5):670-9
pubmed: 25180241
Antimicrob Agents Chemother. 2014 Dec;58(12):7032-40
pubmed: 25199781
J Infect Dis. 2015 Apr 15;211(8):1352-5
pubmed: 25367300
Antimicrob Agents Chemother. 2015 Jan;59(1):437-43
pubmed: 25367912
Malar J. 2014 Dec 04;13:472
pubmed: 25471113
Science. 2015 Jan 23;347(6220):428-31
pubmed: 25502314
Sci Rep. 2015 Feb 06;5:8308
pubmed: 25655315
Lancet Infect Dis. 2015 Jun;15(6):683-91
pubmed: 25877962
J Infect Dis. 2015 Nov 15;212(10):1629-35
pubmed: 25910630
Am J Trop Med Hyg. 2015 Jun;92(6):1202-6
pubmed: 25918205
Antimicrob Agents Chemother. 2015 Aug;59(8):4719-26
pubmed: 26014949
Emerg Infect Dis. 2015 Jul;21(7):1237-9
pubmed: 26079933
Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):11672-7
pubmed: 26261345
Antimicrob Agents Chemother. 2015 Nov;59(11):6952-9
pubmed: 26324266
Malar J. 2015 Sep 22;14:359
pubmed: 26390866
Antimicrob Agents Chemother. 2015 Dec;59(12):7878-81
pubmed: 26416865
Antimicrob Agents Chemother. 2015 Oct 26;60(1):624-7
pubmed: 26503652
BMC Med. 2015 Dec 22;13:305
pubmed: 26695060
Lancet Infect Dis. 2016 Mar;16(3):357-65
pubmed: 26774243
Malar J. 2016 Jan 22;15:36
pubmed: 26801909
Antimicrob Agents Chemother. 2016 Jul 22;60(8):5010-3
pubmed: 27185795
N Engl J Med. 2016 Jun 23;374(25):2453-64
pubmed: 27332904
Emerg Infect Dis. 2016 Aug;22(8):1503-5
pubmed: 27433806
Malar J. 2016 Jul 22;15(1):381
pubmed: 27449110
Am J Trop Med Hyg. 2016 Nov 2;95(5):1054-1060
pubmed: 27549635
Sci Rep. 2016 Oct 03;6:33891
pubmed: 27694982
Malar J. 2016 Oct 21;15(1):519
pubmed: 27769299
Malar J. 2016 Nov 3;15(1):525
pubmed: 27809844
Lancet Infect Dis. 2017 Feb;17(2):164-173
pubmed: 27818095
Lancet Infect Dis. 2017 Feb;17(2):174-183
pubmed: 27818097
Antimicrob Agents Chemother. 2017 Feb 23;61(3):
pubmed: 28052850
Malar J. 2017 Jan 13;16(1):27
pubmed: 28086775
Antimicrob Agents Chemother. 2017 Feb 23;61(3):
pubmed: 28137810
Malar J. 2017 Feb 2;16(1):62
pubmed: 28153004
Lancet Infect Dis. 2017 May;17(5):491-497
pubmed: 28161569
N Engl J Med. 2017 Mar 9;376(10):991-3
pubmed: 28225668
Emerg Infect Dis. 2017 Apr;23(4):715-717
pubmed: 28322709
Int J Antimicrob Agents. 2017 Jun;49(6):754-756
pubmed: 28450175
Malar J. 2017 May 12;16(1):195
pubmed: 28494763
BMC Infect Dis. 2017 Aug 10;17(1):560
pubmed: 28797235
Malar J. 2017 Sep 13;16(1):372
pubmed: 28903755
Antimicrob Agents Chemother. 2017 Nov 22;61(12):
pubmed: 28923866
J Infect Dis. 2017 Aug 15;216(4):468-476
pubmed: 28931241
J Infect Dis. 2017 Nov 15;216(8):1008-1017
pubmed: 28968782
Malar J. 2017 Nov 25;16(1):480
pubmed: 29178921
Antimicrob Agents Chemother. 2018 Jan 25;62(2):
pubmed: 29229635
Malar J. 2018 Jan 25;17(1):52
pubmed: 29370844
Malar J. 2018 Mar 12;17(1):108
pubmed: 29530046
Parasit Vectors. 2018 Mar 12;11(1):175
pubmed: 29530100
Lancet. 2018 Apr 7;391(10128):1378-1390
pubmed: 29606364
Malar J. 2018 Apr 3;17(1):144
pubmed: 29615039
J Infect Dis. 2018 Jul 2;218(3):434-442
pubmed: 29659945
Emerg Infect Dis. 2018 Aug;24(8):
pubmed: 29798744
Malar J. 2018 Jul 5;17(1):248
pubmed: 29976207
Infection. 2018 Dec;46(6):867-870
pubmed: 29980936
Malar J. 2018 Jul 11;17(1):261
pubmed: 29996849
PLoS Med. 2018 Jul 17;15(7):e1002606
pubmed: 30016328
Nat Commun. 2018 Aug 17;9(1):3314
pubmed: 30115924
Antimicrob Agents Chemother. 2018 Oct 24;62(11):
pubmed: 30181370
Infect Drug Resist. 2018 Aug 28;11:1329-1338
pubmed: 30214253
Malar J. 2018 Oct 17;17(1):369
pubmed: 30333022
Malar J. 2018 Oct 26;17(1):391
pubmed: 30367653
Trials. 2018 Nov 6;19(1):610
pubmed: 30400934
Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):12799-12804
pubmed: 30420498
Int J Parasitol Drugs Drug Resist. 2019 Apr;9:16-22
pubmed: 30580023
Antimicrob Agents Chemother. 2019 Apr 25;63(5):
pubmed: 30782997
Trans R Soc Trop Med Hyg. 2019 Jun 1;113(6):312-319
pubmed: 30892640
Malar J. 2019 Mar 25;18(1):99
pubmed: 30909922
Lancet. 2019 Apr 6;393(10179):1428-1439
pubmed: 30910321